Efficacy of Cannabidiol for the Treatment of Canine Epilepsy
dc: 12/20/2017
Cannabidiol (CBD), a prominent non-psychotropic component of the Cannabis sativa plant, has been shown to have anti-convulsant properties, offering promise as a treatment for canine epilepsy. This is a double-blinded, placebo-controlled, crossover clinical trial, in which client-owned dogs with uncontrolled epilepsy can be enrolled. Each dog will undergo a seizure workup, including bloodwork, magnetic resonance imaging and a spinal tap. The dogs will receive either a placebo or CBD in addition to their standard AED protocol for 12 weeks and then the opposite drug for an additional 12 weeks. Seizure frequency and medication side effects will be monitored by the owners via a seizure log and questionnaire. CBD plasma concentrations, routine bloodwork and serial physical examinations will be performed. The primary goal of the study is to determine the efficacy of CBD in the treatment of canine epilepsy. If CBD is effective in decreasing seizure frequency, it has the potential of saving the lives of dogs that are euthanized for uncontrolled epilepsy.
Read more about AKC CHF grant #02323 here!
More Information
Name: Stephanie McGrath and/or research assistants
Email: CSUNeuroTrials@colostate.edu and/or stephanie.mcgrath@colostate.edu
Phone: (970) 305-0455
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
